JPMorgan Leads Big Bank Surge in Q1 2026 as Dimon Sounds Alarm
JPMorgan profits surged 15% to $16.5B in Q1 2026, leading a blockbuster quarter for Wall Street banks. But CEO Dimon is warning of an increasingly complex risk environment.
Bruno
Fed Rate-Cut Odds Hit 40% as Iran Peace Talks Ease Oil Fears
Money markets repriced Fed rate-cut odds from below 10% to 40% as US-Iran peace talk optimism sent oil prices lower. Here is what bond investors need to know.
Netflix Q1 2026 Earnings Preview: What Investors Are Watching
Netflix reports Q1 2026 earnings on April 16. Here’s what Wall Street is watching: ad-tier growth, engagement metrics, margins, and macro risks.
IMF Slashes Global Growth Outlook: Capital Markets on Alert
The IMF has cut its 2026 global growth outlook amid the Iran energy crisis, sticky inflation, and US-China tariffs. Here’s what capital markets need to watch.
Apple, Meta, and Alphabet Face the AI Test in Q1 2026 Earnings
Apple, Meta, and Alphabet report Q1 2026 earnings this month. Here’s what Wall Street expects and why AI returns are the central question.
Gold Near $5,000: Inside the 2026 Bullion Rally
Gold touched nearly $5,000 per ounce in early 2026 before pulling back to $4,811. Here’s what’s driving the historic rally — and whether it can last.
Consumer Confidence Hits Record Low: Iran Energy Shock
US consumer confidence hit a record low in April 2026 as the Iran energy shock drives CPI to 3.3% and stagflation fears deepen across markets.
Bitcoin Hits $74K: What US-Iran Peace Talks Mean for Risk Markets
Bitcoin surged above $74,000 to a one-month high as US-Iran peace negotiations lifted risk appetite across crypto and equity markets. Here’s what it signals.
March Home Sales Miss: What It Means for Housing Stocks
U.S. existing home sales fell 3.6% in March—far worse than the 0.7% consensus estimate. What the miss means for homebuilder stocks, REITs, and mortgage markets.
Pharma Giants Race to Harness AI — What It Means for Drug Stocks
From protein folding to clinical trials, AI is transforming drug discovery. Novo Nordisk’s OpenAI deal is the latest signal for pharma investors.